ACADIA Pharmaceuticals
ACAD
17.11
-0.48
-2.73%
ACADIA Pharmaceuticals
US · ACAD
#2404 by market cap
Listed 1970
17.11
-0.48
-2.73%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
A-
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1 1
■ Upgrades■ Downgrades
- 1 upgrade vs 1 downgrade among tracked analyst rating changes.
- Most recent: UBS moved from Buy to Hold on 2026-10-13.
Analyst consensus 13 analysts
Buy
Avg price target 31.77 +85.7%
Price target rangecurrent 17.11
Low23.00
Avg31.77
High38.00
Buy 77%
Hold 23%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-13 | Morgan Stanley | -- | Hold | 24.00 |
| 2026-11-10 | BofA Securities | -- | Buy | 31.00 |
| 2026-11-09 | BMO Capital | -- | Buy | 34.00 |
| 2026-11-06 | CCORF | -- | Buy | 38.00 |
| 2026-11-05 | TD Cowen | -- | Buy | 37.00 |
| 2026-11-05 | BofA Securities | -- | Buy | -- |
| 2026-11-05 | Morgan Stanley | -- | Hold | 28.00 |
| 2026-11-05 | Oppenheimer | -- | Hold | 23.00 |
| 2026-11-05 | RBC Capital | -- | Buy | 38.00 |
| 2026-11-04 | BMO Capital | -- | Buy | 34.00 |
| 2026-10-19 | Needham | -- | Buy | 35.00 |
| 2026-10-14 | UBS | -- | Hold | 23.00 |
| 2026-10-13 | UBS | -- | Hold | 23.00 |
| 2026-10-12 | BMO Capital | -- | Buy | 34.00 |
| 2026-10-09 | BofA Securities | -- | Buy | 31.00 |
| 2026-10-08 | RBC Capital | -- | Buy | 36.00 |
| 2026-10-05 | RBC Capital | -- | Buy | 37.00 |
| 2026-09-25 | CCORF | -- | Buy | 36.00 |
| 2026-09-25 | Citizens JMP | -- | Buy | 33.00 |
| 2026-09-25 | Deutsche Bank | -- | Buy | 31.00 |
| 2026-09-25 | Needham | -- | Buy | 35.00 |
| 2026-09-25 | BMO Capital | -- | Buy | 34.00 |
| 2026-09-25 | Citi | -- | Buy | 33.00 |
| 2026-09-25 | H.C. Wainwright | -- | Buy | 33.00 |
| 2026-09-24 | BofA Securities | -- | Buy | 31.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-10-13 | UBS | Buy → Hold | 23.00 |
| 2026-03-25 | BofA Securities | Hold → Buy | 29.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-04 | After close | ±6.48% | -1.07% (in line) |
| 2026/Q2 | 2026-08-04 | After close | ±9.58% | +6.08% (in line) |
| 2026/Q1 | 2026-05-06 | After close | ±7.06% | +5.03% (in line) |
| 2025/Q4 | 2026-02-25 | After close | ±9.52% | -1.32% (in line) |
| 2025/Q3 | 2025-11-05 | After close | ±12.70% | -3.05% (in line) |
| 2025/Q2 | 2025-08-06 | After close | ±10.61% | +2.52% (in line) |
| 2025/Q1 | 2025-05-07 | After close | ±13.22% | +14.31% (beat) |
| 2024/Q4 | 2025-02-26 | After close | ±14.04% | +1.79% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±15.79% | +8.93% (in line) |
| 2024/Q2 | 2024-08-06 | After close | ±20.38% | -19.52% (in line) |
| 2024/Q1 | 2024-05-08 | After close | ±17.34% | -11.21% (in line) |
| 2023/Q4 | 2024-02-27 | After close | ±15.33% | -9.92% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
ACADIA Pharmaceuticals discussion 0 comments